Home
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Blood Glucose Articles
Popular Blood Glucose Articles
Highly Recommended Blood Glucose Articles
Email to a Friend
Send a link to this page to your friends and colleagues.
Merck Announces FDA Acceptance of NDA for Januvia
An investigational once-daily medicine for the treatment of type 2 diabetes
By October of this year, Merck & Co., Inc., expects the FDA to rule on its novel type 2 drug Januvia (sitagliptin phosphate). On February 15, 2006, the FDA accepted Merck’s New Drug Application (NDA) for Januvia for standard review.
Januvia is an investigational once-daily medicine for the treatment of type 2 diabetes. Merck says that if approved, Januvia would be the first in a new class of oral medications called DPP-4 inhibitors, which enhance the body’s own ability to lower blood glucose when it is elevated.
“Based on our clinical studies, we believe Januvia represents a new and different approach to the treatment of type 2 diabetes,” says Richard T. Clark, Merck’s chief executive officer and president. “Merck is committed to developing innovative therapies that offer advances in the treatment of serious diseases like diabetes and demonstrate clear value to patients, payors and physicians.”
The most common side effects of Januvia reported in clinical studies were stuffy or runny nose and sore throat, headache, diarrhea and joint pain.
For more information, log on to www.merck.com.
What are DPP-4 inhibitors?
DPP-4 inhibitors work by enhancing the body’s incretin system, which works to lower blood glucose. When blood glucose is elevated, incretins work in two ways to help the body regulate high blood glucose levels: They trigger the pancreas to increase insulin production, and they signal the liver to stop producing glucose. DPP-4 inhibitors enhance the body’s own ability to control blood glucose levels by increasing the active levels of incretin hormones in the body, helping to decrease blood glucose levels in patients with type 2 diabetes.
Source: Merck & Co., Inc.
Categories: Blood Glucose, Diabetes, Diabetes, Insulin, Januvia, Medications, Type 2 Issues, Type 2 Medications
You May Also Be Interested In...
-
Diabetes Health
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
-
Topics
- Diabetic / Diabetes Health
- Type 1 / 1.5 Diabetes
- Type 2 Diabetes
- Blood Glucose / Sugar
- High/Low Blood Sugar / Fast Acting Glucose
- Insulin- Pumps, Pens & Syringes
- Continuous Glucose Monitors, CGM, Infusion Sets
- Type 2 Medications
- Hyperglycemia
- Hypoglycemia
Comments
Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.
When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.
For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.
Don't have your Diabetes Health Username? Register now and add your comments to all our content.
Register...
Register your Diabetes Health Username here.
Have Your Say...